Humulin N (Insulin Human (Rdna))

Humulin N is a recombinant human insulin (insulin human) supplied as an injectable solution for subcutaneous administration. It is a prescription‑only product marketed in the European Union and is classified as an antidiabetic insulin (ATC code A10AC01). The formulation provides a neutral (N) intermediate‑acting insulin profile, allowing once‑or twice‑daily dosing to help maintain basal glucose control in patients with diabetes as part of a comprehensive diabetes management plan.

Humulin N is indicated for the management of blood glucose in adults and children with diabetes when basal insulin coverage is required.

- Type 1 diabetes mellitus as part of a basal‑bolus regimen. - Type 2 diabetes mellitus when oral agents or other insulins do not achieve target glycaemic control. - Adjunct therapy during pregnancy or lactation when recommended by a healthcare professional. - Use in combination with rapid‑acting insulin analogues for flexible dosing schedules.

Like all insulin preparations, Humulin N may cause adverse reactions ranging from mild injection‑site irritation to rare but serious systemic events.

Common: - Hypoglycemia (low blood glucose) – the most frequent effect. - Injection‑site redness, swelling or itching. - Lipodystrophy (localized fat loss or accumulation). - Weight gain due to improved glucose utilization.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Edema or fluid retention, especially in patients with cardiac or renal disease. - Hypersensitivity with eosinophilia or serum‑sickness‑like syndrome.

Healthcare professionals should assess individual risk factors before initiating Humulin N and monitor patients regularly for safety concerns.

- Adjust dose when renal or hepatic impairment is present. - Use caution in patients with a history of severe hypoglycemia or unawareness. - Review concomitant medications that may mask hypoglycemia symptoms. - Avoid use in patients with known hypersensitivity to human insulin or any excipients. - Monitor weight, fluid status, and signs of edema during therapy. - Pregnancy and lactation decisions should be guided by a prescriber.

Humulin N can interact with other drugs that affect glucose metabolism or insulin action, requiring dose adjustments or close monitoring.

Avoid: - Concurrent use of other rapid‑acting insulins without proper dose reduction. - Combination with meglitinides or sulfonylureas that increase hypoglycemia risk.

Use with caution: - Beta‑blockers may mask hypoglycemia symptoms. - Corticosteroids, thiazide diuretics, and oral contraceptives can raise insulin requirements. - Alcohol consumption may potentiate hypoglycemia. - ACE inhibitors or ARBs may enhance insulin sensitivity, affecting dose needs.